![]() |
|
|
Vol. 63, Issue 1, 159-166, January 2003
Dipartimento di Medicina Interna, Università di Firenze,
Firenze, Italy (A.M., P.P., V.C.); U.O. Oncologia Medica, Ospedale San
Donato, Arezzo, Italy (S.G.); Department of Chemistry, Yale University,
New Haven, Connecticut (A.D.H.); and Drug Discovery Program, H. Lee
Moffitt Cancer Center and the Department of Biochemistry and Molecular
Biology, University of South Florida, Tampa, Florida (S.M.S.)
Farnesyltransferase inhibitors (FTIs) block the growth of tumor cells
in vitro and in vivo with minimal toxicity toward normal cells. In
general, inhibition of protein farnesylation results in
G0/G1 cell cycle block, G2/M cell
cycle arrest, or has no effect on cell cycle progression. One aspect of
FTI biology that is poorly understood is the ability of these drugs to
induce cancer cell growth arrest at the G2/M phase of cell
cycle. In the present study, we investigated the effects of the
farnesyltransferase inhibitor FTI-277 on two human liver cancer
cell lines, HepG2 and Huh7. Treatment of these cells with FTI-277
inhibited Ras farnesylation in a dose-dependent manner. Both HepG2 and
Huh7 cell growth was inhibited by FTI-277 and cells accumulated at the
G2/M phase of the cell cycle. In HepG2 and Huh7 cells,
FTI-277 induced an up-regulation of the cyclin-dependent kinase
inhibitor p27Kip1 without affecting the
cellular levels of p53 and p21Waf1. This event
correlated with reduced activity of the cyclin-dependent kinase 2 and
cyclin-dependent kinase 1. Moreover, increased expression of Bcl-2
protein was observed in HepG2 and Huh7 cells treated with FTI-277, and
this was coincidental with reduced association between Raf-1 and Bcl-2.
Finally, transient transfection of a dominant-negative Ras allele
induced Bcl-2 expression and reduced Bcl-2/Raf-1 association
demonstrating a requirement for Ras. Taken together, these findings
show that increased expression of p27Kip1 and
Bcl-2 is concomitant with altered association between Ras, Raf-1 and
Bcl-2 and suggest that this is responsible for the growth-inhibitory properties of FTI-277.
This article has been cited by other articles:
![]() |
V. Carloni, F. Vizzutti, and P. Pantaleo Farnesyltransferase Inhibitor, ABT-100, Is a Potent Liver Cancer Chemopreventive Agent Clin. Cancer Res., June 1, 2005; 11(11): 4266 - 4274. [Abstract] [Full Text] [PDF] |
||||